newsfilter
← Latest News
GlobeNewswire·

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

  • AEON Biopharma announced positive results from a pilot forced degradation study comparing ABP-450 to BOTOX® under thermal & oxidative stress conditions.
  • Under thermal stress, both molecules lost potency at comparable rates, each following a similar trajectory of rapid initial loss reaching approximately half of initial observed potency by day 14.
  • Under oxidative stress, methionine sites in both molecules oxidized to a comparable magnitude at two hydrogen peroxide concentrations, indicating similar higher-order structural characteristics.
  • The pilot study was not powered for formal statistical comparison but provides additional analytical evidence supporting the structural comparability of ABP-450 to BOTOX®.
  • Based on these findings, AEON plans to initiate a formally powered multi-lot comparability study evaluating ABP-450 lots against BOTOX® comparator lots in the first half of 2027.
  • The study results add an independent dimension to AEON's totality-of-the-evidence approach for its planned 351(k) BLA submission for therapeutic indications in the U.S.
  • ABP-450 is the same botulinum toxin complex approved for cosmetic use by Evolus under the name Jeuveau®, manufactured by Daewoong Pharmaceutical in an FDA-authorized facility.